Last reviewed · How we verify
talc powder
Talc powder acts as a sclerosing agent that causes inflammation and adhesion of serosal surfaces to prevent fluid reaccumulation.
Talc powder acts as a sclerosing agent that causes inflammation and adhesion of serosal surfaces to prevent fluid reaccumulation. Used for Malignant pleural effusion, Malignant peritoneal effusion, Malignant pericardial effusion.
At a glance
| Generic name | talc powder |
|---|---|
| Sponsor | Chinese University of Hong Kong |
| Drug class | Sclerosing agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
When instilled into body cavities (pleural, peritoneal, or pericardial), talc particles trigger an inflammatory response that leads to fibrosis and adhesion of the visceral and parietal surfaces. This mechanical obliteration of the space prevents malignant effusions from reaccumulating. The mechanism is primarily physical and inflammatory rather than pharmacological.
Approved indications
- Malignant pleural effusion
- Malignant peritoneal effusion
- Malignant pericardial effusion
Common side effects
- Chest pain or abdominal pain
- Fever
- Dyspnea
- Talcosis (chronic lung inflammation from inhalation)
Key clinical trials
- Comparison of Talc Slurry Versus Talc Insufflation: A Study on Effectiveness, Safety, and Hospital Outcomes in Pleurodesis (NA)
- Evaluation of the Efficacy of Compression With Tight Surgical Gloves in Patients With Taxane-based Therapy (NA)
- Stop Air Leak by Talc or Autologous Blood Patch Therapy (PHASE2, PHASE3)
- Tryptophan for Impaired AhR Signaling in Celiac Disease (NA)
- Extracts of Amla, Walnut Leaf, Red Yeast Rice and Olive in Cardiovascular Prevention (PHASE4)
- Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma (PHASE1)
- Vitamin B Complex Improved Exercise Performance and Anti-fatigue (NA)
- Comparison of Laparoscopic Adnexal Mass Extraction Via the Transumbilical and Transvaginal Routes
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- talc powder CI brief — competitive landscape report
- talc powder updates RSS · CI watch RSS
- Chinese University of Hong Kong portfolio CI